Some statements in this presentation are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation
Reform Act of 1995. The words “believe,” “expect,” “anticipate,” “project” and similar expressions, among others, generally identify forwardlooking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties, including the impact of the
COVID-19 pandemic on AbbVie’s operations, results and financial results, that may cause actual results to differ materially from those
indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits
of the Allergan acquisition, failure to effectively integrate Allergan's businesses, challenges to intellectual property, competition from other
products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and
regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors
that may affect AbbVie’s operations is set forth in Item 1A, “Risk Factors,” of AbbVie's 2020 Annual Report on Form 10-K, which has been
filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie
subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes
no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as
required by law.
相关推荐
热门下载
推荐
快速链接
热门标签
关注我们
扫码关注我们
了解更多相关信息